TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23198694
Drug: Chinese diabetes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese diabetes group visit program (12 monthly group visit sessions)
Study: 17403121
Drug: rosiglitazone +
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosiglitazone + metformin (8/2000 mg)
Study: 11136485
Drug: Potassium canrenoate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium canrenoate, 50 mg once daily
Study: 7935635
Drug: Radioiodinated vasoactive
Normalized name: Vasoactive intestinal peptide
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodinated vasoactive intestinal peptide (VIP) administered as a single intravenous bolus injection (300 pmol [1 microgram])
Study: 23617693
Drug: Isotretinoin 5
Normalized name: isotretinoin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 5 mg/day for 16 weeks
Study: 23617693
Drug: Isotretinoin 5
Normalized name: isotretinoin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 5 mg/day after 16 weeks of placebo
Study: 23617693
Drug: Isotretinoin 5
Normalized name: isotretinoin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotretinoin 5 mg/day for 32 weeks
Study: 17655947
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg atorvastatin (low dose)
Study: 17655947
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg atorvastatin (high dose)
Study: 12462550
Drug: Estrogen-progestin replacement
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen-progestin replacement therapy (HRT)
Study: 7740333
Drug: IV vinorelbine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV vinorelbine (first-line therapy)
Study: 2201742
Drug: Ciprofloxacin, 500
Normalized name: Ciprofloxacin, 500 mg/5 mL oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin, 500 mg every 12 h for 5 days
Study: 2201742
Drug: Ampicillin, 500
Normalized name: Ampicillin, 500 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin, 500 mg every 6 h for 5 days
Study: 7026260
Drug: Sublingual isoxsuprine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual isoxsuprine 20 mg
Study: 7026260
Drug: Oral isoxsuprine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isoxsuprine 20 mg
Study: 28526720
Drug: Trabectedin 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin 1.2 mg/m2
Study: 23722126
Drug: 1% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% chlorhexidine gel applied twice a day for one week
Study: 23722126
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine gel applied twice a day for one week
Study: 21321426
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of Panax ginseng (PG)
Study: 19761681
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blocker (ARB; irbesartan 300 mg/day or valsartan 160 mg/day)
Study: 19761681
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitor (ACEi; fosinopril 10 mg/day or quinapril 20 mg/day)
Study: 11273588
Drug: FUFOL (monthly
Approvals — FDA: no, EMA: no, PMDA: no
Description: FUFOL (monthly regimen)
Study: 10896408
Drug: Halofantrine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (1500 mg)
Study: 10896408
Drug: Chloroquine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (1500 mg)
Study: 354330
Drug: Conventional amitriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional amitriptyline tablets (Saroten)
Study: 26840887
Drug: Collagen hydrolysate
Normalized name: collagen, hydrolyzed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collagen hydrolysate with a lower content of bioactive collagen peptides (L-CP)
Study: 16000280
Drug: 123I‐PE2I bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 123I‐PE2I bolus injection
Study: 16000280
Drug: Combined bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined bolus and constant infusion of 123I‐PE2I
Study: 12833584
Drug: Candesartan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (4 mg, once daily) in combination with ramipril
Study: 12833584
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in combination with ramipril
Study: 10567194
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of sustained‐release nicardipine hydrochloride twice daily
Study: 10567194
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of trichlormethiazide once daily
Study: 1818788
Drug: Nitrate therapy
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate therapy
Study: 24663014
Drug: Overall pharmacokinetics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall pharmacokinetics of rifampin and isoniazid
Study: 12789223
Drug: Other Antihistamines
Normalized name: Other antihistamines for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other Antihistamines (OAH)
Study: 12789223
Drug: Other Antihistamines
Normalized name: Other antihistamines for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other Antihistamines (OAH) (first trimester)
Study: 9082488
Drug: Aspirin treatment
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin treatment for primary prevention of coronary heart disease
Study: 1634452
Drug: Theolan preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theolan preparation (once a day)
Study: 1634452
Drug: Theolan preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theolan preparation (twice a day)
Study: 6499384
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate with bisacodyl (oral or rectal)
Study: 25237668
Drug: Computer-guided implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-guided implant placement aided with templates
Study: 25237668
Drug: Conventional implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional implant placement without templates
Study: 8683286
Drug: Nimodipine treatment
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine treatment (intravenous and oral) for 3 weeks
Study: 8683286
Drug: Nimodipine treatment
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nimodipine treatment (intravenous and oral) for 3 weeks (compliant patients only)
Study: 1803712
Drug: Estrogen Receptor
Normalized name: Estrogen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen Receptor (ER) positive status
Study: 1803712
Drug: Estrogen Receptor
Normalized name: Estrogen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen Receptor (ER) levels greater than 100 fmol/mg protein
Study: 1803712
Drug: Progesterone Receptor
Normalized name: Progesterone receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone Receptor (PgR) status
Study: 1803712
Drug: Progesterone Receptor
Normalized name: Progesterone receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone Receptor (PgR) levels
Study: 6360027
Drug: Methysergide, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methysergide, 8 mg daily
Study: 27302362
Drug: EGCG (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (9 mg/kg per day) plus cognitive training
Study: 12809958
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg QD
Study: 12809958
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg QD
Study: 9129860
Drug: Lovastatin monotherapy
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin monotherapy
Study: 1548825
Drug: Aztreonam 100
Normalized name: aztreonam 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam 100 mg three times a day for 5 days
Study: 30299178
Drug: Ginger root
Normalized name: Ginger Root
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger root (1.425 g/day)
Study: 29809257
Drug: Osteopathic Manipulative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopathic Manipulative Therapy (OMTh)
Study: 15701612
Drug: Betamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betamethasone (4 mL of 2% xylocaine and 1 mL (6 mg) of betamethasone)
Study: 15701612
Drug: Xylocaine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xylocaine (5 mL of 2% xylocaine alone)
Study: 10847423
Drug: 0.5 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g/kg alcohol in orange-flavoured drink
Study: 8925753
Drug: AVE micro-stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVE micro-stent implantation with dual antiaggregation treatment (500 mg ticlopidine and 100 mg aspirin daily for 6 weeks)
Study: 7709692
Drug: human follicular
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: human follicular fluid (hFF) treatment
Study: 7709692
Drug: mini‐CDPG treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: mini‐CDPG treatment
Study: 29673355
Drug: Mirabegron (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (25 mg for 4 weeks, then 50 mg for 4 weeks)
Study: 29673355
Drug: Tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine ER (4 mg for 8 weeks)
Study: 26921934
Drug: Multicomponent non‐pharmacologic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multicomponent non‐pharmacologic intervention (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drug chart review, elimination, oxygenation, pain)
Study: 23545834
Drug: GnRH-antagonist protocol
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH-antagonist protocol with highly purified uFSH (Bravelle®) 300 IU/day and 0.25 mg/day GnRH-antagonist starting on cycle day 19-21
Study: 23545834
Drug: Conventional GnRH-antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional GnRH-antagonist protocol with 150-225 rFSH or HP-HMG/day
Study: 10653877
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus cisplatin (135 mg/m² and 250 mg/m²)
Study: 10653877
Drug: Etoposide plus
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide plus cisplatin (100 mg/m² daily on days 1 to 3, with cisplatin 75 mg/m²)
Study: 29587582
Drug: Upfront spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upfront spironolactone 25 mg OD
Study: 29587582
Drug: Discharge spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Discharge spironolactone 25 mg OD
Study: 20795383
Drug: Immunovac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunovac vaccine with basic therapy
Study: 20795383
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with basic therapy only
Study: 20795383
Drug: Immunovac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunovac vaccine
Study: 18421050
Drug: Anthracycline (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline (alone or in combination)
Study: 10823095
Drug: Amethocaine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amethocaine patch
Study: 10823095
Drug: Ametop gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ametop gel
Study: 10823095
Drug: Amethocaine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amethocaine patch vs Ametop gel
Study: 30663107
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg b.d.
Study: 28463028
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml 1% lidocaine paracervical block
Study: 28463028
Drug: 400 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 µg oral misoprostol
Study: 27565425
Drug: C‐Mill therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: C‐Mill therapy (therapy with augmented reality)
Study: 27565425
Drug: FALLS program
Approvals — FDA: no, EMA: no, PMDA: no
Description: FALLS program (a conventional therapy program)
Study: 16255339
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate infusion (5 mEq/kg over 1 hour, followed by 5‐6 mEq/kg daily until recovery or death)
Study: 16255339
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard treatment without high doses of sodium bicarbonate)
Study: 7612060
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg ibuprofen racemate tid + placebo
Study: 7266950
Drug: Intravenous ritodrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ritodrine in a 0.1 wt/vol% solution of isotonic saline (N = 12)
Study: 7266950
Drug: Intravenous ritodrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ritodrine in isotonic glucose (N = 11)
Study: 28292361
Drug: Per rectal
Normalized name: phenylephrine/pyrilamine/diper RECTAL OINTMENT (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Per rectal misoprostol (800 µgm)
Study: 20187995
Drug: Pear-carrot-sea buckthorn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pear-carrot-sea buckthorn (PCS) shots containing JA inulin (5 g/d)
Study: 20187995
Drug: Plum-pear-beetroot (PPB)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plum-pear-beetroot (PPB) shots containing JA inulin (5 g/d)
Study: 18550472
Drug: Biopsy diagnoses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biopsy diagnoses by clinical center (CC) pathologists
Study: 12500511
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline 0.075 ml/kg (control)
Study: 10036953
Drug: Lansoprazole (LPZ)
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole (LPZ) 30 mg, Clarithromycin (CAM) 400 mg, Metronidazole (MTZ) 500 mg (LCM group)
Study: 10036953
Drug: Ranitidine (RNT)
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine (RNT) 300 mg, Clarithromycin (CAM) 400 mg, Metronidazole (MTZ) 500 mg (RCM group)
Study: 2257961
Drug: 2% butoconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% butoconazole nitrate cream used for 3 days
Study: 2257961
Drug: 1% econazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% econazole nitrate cream used for 7 days
Study: 7066167
Drug: Meladinine tablets
Normalized name: Melaniline
DrugBank: Diphenylguanidine (DB14191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meladinine tablets (Basotherm)
Study: 7066167
Drug: Oxsoralen capsules
Normalized name: Psoralen
DrugBank: Psoralen (DB18665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxsoralen capsules (Elder)
Study: 30431298
Drug: Light therapy
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light therapy for 3 weeks
Study: 26351345
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy with concurrent radiation therapy (RT)
Study: 26351345
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy alone (without RT)
Study: 21083673
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of esomeprazole twice daily for 12 weeks
Study: 15107193
Drug: Lisuride 0.2
Normalized name: lisuride 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisuride 0.2 mg
Study: 11172176
Drug: Heptavalent pneumococcal
Normalized name: botulinum neurotoxin B immune FAB2
DrugBank: Equine Botulinum Neurotoxin B Immune FAB2 (DB13903)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heptavalent pneumococcal polysaccharide conjugate vaccine
Study: 9629950
Drug: Citalopram infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram infusion (40 mg/day)
Study: 9629950
Drug: Citalopram oral
Normalized name: citalopram Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram oral tablets (40 mg/day)
Study: 31608532
Drug: Rikkunshito (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rikkunshito (2.5 g t.i.d. for 4 weeks)
Study: 30246183
Drug: 5 mm
Normalized name: SUR-FIT 45 mm Wafer, Small
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mm long implants
Study: 30246183
Drug: 11.5 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11.5 mm long implants
Study: 30246183
Drug: Short implants
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short implants (5 mm)
Study: 30246183
Drug: Long implants
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long implants (11.5 mm)
Study: 21147907
Drug: 5-day zinc
Normalized name: zinc sulfate 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-day zinc treatment
Study: 21147907
Drug: 10-day zinc
Normalized name: zinc gluconate
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-day zinc treatment
Study: 12718838
Drug: Separate DTPw‐HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate DTPw‐HBV and Hib vaccines
Study: 27130714
Drug: Broccoli sprouts
Normalized name: broccoli sprout extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broccoli sprouts (BS) 100 g daily for 3 days
Study: 27130714
Drug: Alfalfa sprouts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfalfa sprouts (AS) 100 g daily for 3 days (Control)
Study: 22712582
Drug: Intraprostatic injection
Normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraprostatic injection of 200 U OnabotulinumtoxinA (BTX-A)
Study: 21130386
Drug: CIC‐HFA 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIC‐HFA 80 μg
Study: 21130386
Drug: CIC‐HFA 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIC‐HFA 160 μg
Study: 17034536
Drug: Topical methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methyl aminolaevulinate (MAL)-photodynamic therapy (PDT)
Study: 10914048
Drug: Diazepam premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam premedication (oral, 1 hour before BMP)
Study: 10914048
Drug: Placebo premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo premedication (oral, 1 hour before BMP)
Study: 8623975
Drug: Nalbuphine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nalbuphine 2.5 mg/h, PSA nalbuphine 1 mg
Study: 1564028
Drug: methylphenidate and
Normalized name: dexmethylphenidate and serdexmethylphenidate
Approvals — FDA: no, EMA: no, PMDA: no
Description: methylphenidate and lithium carbonate in combination
Study: 3935644
Drug: Pelletized cromolyn
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelletized cromolyn (cromolyn sodium, 20 mg)
Study: 3935644
Drug: Cromolyn blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn blend (cromolyn sodium, 20 mg + lactose, 20 mg)
Study: 31707149
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (ASA) 81 mg
Study: 31707149
Drug: Esomeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (40 mg) twice daily
Study: 28222577
Drug: SUPP: 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: SUPP: 500 mg alpha glycerophosphocholine [AGPC], 250 mg uridine‐5'‐monophosphate, and 1500 mg DHA
Study: 24481133
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice supplementation (0.5 l/day organic beetroot juice containing about 5.5 mmol of NO₃⁻)
Study: 20353024
Drug: Pinaverium bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide tablet (PVB)
Study: 18959094
Drug: Diuretics (particularly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics (particularly loop diuretics)
Study: 18959094
Drug: Aldosterone antagonists
Normalized name: Aldosterone antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aldosterone antagonists (spironolactone and eplerenone)
Study: 16087795
Drug: GM‐CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GM‐CSF (10 microg/kg, subcutaneously applied for 14 days, total of 7 injections)
Study: 7742149
Drug: Renin inhibitor
Normalized name: Renin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin inhibitor
Study: 1836569
Drug: Cefazolin or
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefazolin or cefotaxime (3 doses of 1 g administered 8-hourly)
Study: 1836569
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 single dose of 1 g)
Study: 6112844
Drug: Beta-blockers (general)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (general)
Study: 21241214
Drug: Extended-dose nevirapine
Normalized name: nevirapine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-dose nevirapine (ED-NVP)
Study: 19119321
Drug: Single-dose nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose nevirapine (SD-NVP)
Study: 16890682
Drug: Uriston (P.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uriston (P. niruri extract) 2 gm daily for at least 3 months (group 1)
Study: 14520089
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics for AOM
Study: 14520089
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for OME after untreated AOM
Study: 14520089
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for OME of unknown duration
Study: 14520089
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment for chronic OME
Study: 8406967
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no post space preparation)